Methamphetamine Abuse ICD-10: A Clinical Guide to F15 Coding, Documentation, and Treatment Planning

In emergency departments across the American West and Midwest, methamphetamine is the dominant presenting substance. In outpatient behavioral health settings, it is equally pervasive. Yet when clinicians reach for the ICD-10 code to document methamphetamine abuse, they often find themselves navigating a deceptively complex classification system. The Alphabetic Index routes "methamphetamine" to "stimulant NEC" (not elsewhere classified), which lands in the F15 family. But F15 is a broad category covering amphetamines, prescription stimulants, and even caffeine. The choice of the correct code depends on the patient's severity, the presence of complications, and the stage of recovery.

This article provides a comprehensive guide to ICD-10 coding for methamphetamine use disorder. It covers the F15 code hierarchy, the distinction between abuse and dependence, the documentation requirements that protect against audit risk, and the treatment implications of accurate coding.

The F15 Code Family: Understanding the Structure

The ICD-10-CM category F15 (Other stimulant related disorders) encompasses methamphetamine, amphetamines, prescription stimulants used outside therapeutic intent, and, surprisingly to most coders, caffeine. The code family is organised into three stems, each corresponding to a severity level in the DSM-5-TR framework:

This three-stem structure persists in ICD-10-CM even though DSM-5-TR no longer separates "abuse" and "dependence" as distinct diagnoses. The DSM-5-TR uses a single stimulant use disorder graded mild, moderate, or severe, but its own coding notes map mild to the .1- codes and moderate/severe to the .2- codes.

Boundary Rules: What F15 Is Not

Two boundary rules prevent the most common miscodes:

• Cocaine is not F15. The FY2026 tabular carries an Excludes2 note pointing cocaine-related disorders to F14.

• MDMA/ecstasy is not F15. The FY2026 tabular lists "ecstasy" as an inclusion term under F16 (hallucinogen related disorders).

The Primary Codes: F15.10, F15.20, and Their Subcodes

F15.10 — Other Stimulant Abuse, Uncomplicated

F15.10 is a billable/specific code that became effective for the 2026 fiscal year on October 1, 2025. It represents what is now called mild methamphetamine use disorder.

When to use F15.10:

• The patient has a documented history of methamphetamine use

• The patient meets 2-3 DSM-5 criteria for stimulant use disorder

• There are no complications such as intoxication delirium, psychotic disorder, or withdrawal symptoms

• There is no evidence of tolerance, withdrawal symptoms, or a compulsive pattern of use that significantly disrupts daily life

Applicable To:

• Amphetamine type substance use disorder, mild

• Methamphetamine abuse (mild use disorder)

Clinical Validation Requirements:

• Patient history of methamphetamine use

• No documented complications such as psychosis

• Ensure the code is used only when the condition is uncomplicated

F15.20 — Other Stimulant Dependence, Uncomplicated

F15.20 is used when the patient exhibits moderate to severe symptoms of methamphetamine dependence. The DSM-5 criteria threshold is 4 or more criteria for moderate/severe stimulant use disorder.

When to use F15.20:

• The patient meets 4 or more DSM-5 criteria for stimulant use disorder

• There is evidence of tolerance, withdrawal, or a compulsive pattern of use

• The dependence is uncomplicated (no psychotic disorder, intoxication, or other complications documented)

Important Documentation Note: Ensure documentation includes the specific DSM-5 criteria met.

F15.12 — Other Stimulant Abuse with Psychotic Disorder

F15.12 is used when methamphetamine abuse is accompanied by psychotic symptoms such as hallucinations or delusions.

When to use F15.12:

• Methamphetamine abuse is documented and

• Psychotic symptoms are present and directly linked to methamphetamine use

• Positive urine toxicology for methamphetamine

Clinical Distinction: F15.12 is for abuse with psychotic symptoms. If the patient has dependence with psychotic symptoms, the correct code is F15.22 (Other stimulant dependence with stimulant-induced psychotic disorder).

F15.25 — Other Stimulant Dependence with Stimulant-Induced Psychotic Disorder

F15.25 is a non-billable/non-specific code that should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.

Subcodes under F15.25:

• F15.250 — Other stimulant dependence with stimulant-induced psychotic disorder with delusions

• F15.251 — Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations

When to use these codes:

• The patient meets criteria for stimulant dependence and

• The dependence is accompanied by a stimulant-induced psychotic disorder

• The psychotic disorder is specified as with delusions (F15.250) or with hallucinations (F15.251)

F15.11 — Other Stimulant Abuse, in Remission

F15.11 is used when methamphetamine abuse is documented as in remission for at least 6 months.

When to use F15.11:

• Documented period of remission for at least 6 months

• No current use or symptoms

• The patient has not relapsed for an extended period

Documentation Requirement: Ensure remission is clearly documented with duration.

The Documentation That Justifies the Code

Auditors and payers scrutinise substance use disorder claims for specific documentation elements. The table below summarises the most common audit flags and the corresponding mitigation strategies.

The DSM-5 Criteria Threshold

ICD-10-CM maps to DSM-5-TR severity levels. Documentation must specify the number of DSM-5 criteria met:

• 2-3 criteria → Mild (F15.10 for abuse)

• 4-5 criteria → Moderate (F15.20 for dependence)

• 6+ criteria → Severe (F15.20 for dependence)

Key Documentation Principle: Ensure documentation specifies the number of DSM-5 criteria met.

Methamphetamine-Induced Psychotic Disorder: A Diagnostic Challenge

Methamphetamine-induced psychosis is one of the most clinically significant complications of methamphetamine use. The psychotic symptoms—paranoia, auditory hallucinations, persecutory delusions—can be indistinguishable from primary psychotic disorders such as schizophrenia.

Clinical Presentation

Methamphetamine-induced psychosis typically presents with:

• Paranoid delusions — often persecutory in nature

• Auditory hallucinations — frequently derogatory or threatening

• Visual hallucinations — less common but possible

• Formal thought disorder — in severe cases

Differential Diagnosis

The critical clinical distinction is whether the psychosis is substance-induced or primary. The key differentiating factors include:

Coding for Methamphetamine-Induced Psychosis

When methamphetamine-induced psychosis is present, the appropriate code depends on the severity of the underlying substance use disorder:

• Abuse + psychosis → F15.12 (Other stimulant abuse with psychotic disorder)

• Dependence + psychosis → F15.22 (Other stimulant dependence with psychotic disorder)

For dependence with psychotic disorder, the more specific subcodes under F15.25 (F15.250 for delusions, F15.251 for hallucinations) may be appropriate.

Treatment Implications of Accurate Coding

The Challenge: No FDA-Approved Medications

One of the fundamental challenges in treating methamphetamine use disorder is that there are no FDA-approved medications for methamphetamine use disorder and no established medical detox protocols. Clinicians must manage acute withdrawal and support early recovery using only symptomatic treatment and behavioural interventions.

Evidence-Based Psychotherapy

Cognitive Behavioral Therapy (CBT) is the most robustly supported psychological intervention for methamphetamine use disorder. CBT can help patients manage depression and anxiety caused by meth use disorder. Other evidence-based approaches include:

• Contingency Management — providing tangible rewards for abstinence

• Motivational Interviewing — enhancing motivation for change

• Community Reinforcement Approach — building a supportive sober network

Pharmacological Management

The British Association for Psychopharmacology guidelines for the management of substance dependence focus primarily on the pharmacological aspects of treatment. However, for methamphetamine use disorder, pharmacological options remain limited. In cases of severe methamphetamine toxicity, hyperactive or agitated patients may be treated with droperidol or haloperidol, which help manage the excess dopamine produced from methamphetamine toxicity.

The Role of the Psychotherapist

For the mental health clinician, accurate coding of methamphetamine use disorder serves several essential functions:

1. Justifying treatment intensity — F15.20 (dependence) supports more intensive intervention than F15.10 (abuse)

2. Documenting complications — F15.12/F15.22 justify treatment for co-occurring psychotic symptoms

3. Tracking remission — F15.11 documents treatment success and supports maintenance therapy

4. Facilitating continuity of care — accurate coding communicates the severity and stage of the disorder to other providers

FAQ

What is the ICD-10 code for methamphetamine abuse?

The ICD-10 code for methamphetamine abuse without complications is F15.10 (Other stimulant abuse, uncomplicated). This code represents mild methamphetamine use disorder. For moderate or severe methamphetamine use disorder, the correct code is F15.20 (Other stimulant dependence, uncomplicated).

What is the difference between F15.10 and F15.20?

F15.10 is used for mild stimulant use disorder (meeting 2-3 DSM-5 criteria). F15.20 is used for moderate or severe stimulant use disorder (meeting 4 or more DSM-5 criteria). The distinction reflects the severity of the condition and justifies different levels of treatment intensity.

When should I use F15.12 instead of F15.10?

Use F15.12 (Other stimulant abuse with psychotic disorder) when methamphetamine abuse is accompanied by psychotic symptoms such as hallucinations or delusions. Documentation must establish a direct link between the psychotic symptoms and methamphetamine use.

What code should I use for methamphetamine-induced psychosis with dependence?

For dependence with stimulant-induced psychotic disorder, use F15.22 (Other stimulant dependence with psychotic disorder). For more specificity, subcodes under F15.25 include F15.250 for with delusions and F15.251 for with hallucinations.

How do I document remission for methamphetamine use disorder?

Use F15.11 (Other stimulant abuse, in remission) when methamphetamine abuse is documented as in remission for at least 6 months. Documentation must clearly state the duration of remission and confirm no current use or symptoms. Ensure remission is clearly documented with duration.

References

1. Behave Health. (2026). ICD-10 F15 — Other Stimulant Related Disorders: Complete Coding Guide.

2. ICD-10 Data. (2026). 2026 ICD-10-CM Diagnosis Code F15.10 — Other stimulant abuse, uncomplicated.

3. ICDcodes.ai. (2026). Methamphetamine Abuse — ICD-10 Documentation Guidelines.

4. Carepatron. (2026). Methamphetamine Abuse ICD-10-CM Codes.

5. ICD-10 Data. (2026). 2026 ICD-10-CM Diagnosis Code F15.25 — Other stimulant dependence with stimulant-induced psychotic disorder.